# PRESS RELEASE

**For Immediate Release**

**Contact**: info@globalcancertechnology.com

## GLOBAL CANCER TECHNOLOGY INITIATES IN VIVO TRIPLE NEGATIVE BREAST CANCER PRECLINICAL TRIALS AT THE UNIVERSITY OF COLORADO

### DR TRACI LYONS, ASSOCIATE PROFESSOR-MEDICAL ONCOLOGY WILL DIRECT THE STUDIES UTILIZING GLOBAL CANCER TECHNOLOGIE'S PROMISING PI3K INHIBITOR DRUG

**San Diego, CA, November 7, 2022** – Global Cancer Technology, Inc. announced today that the University of Colorado, under the guidance of Dr. Traci Lyons, will commence in vivo animal studies utilizing the companies highly promising PI3K inhibitor drug. "Global Cancer Technology is developing a PI3K inhibitor compound, GCT.BR.1, that has been shown to induce growth arrest, increase sensitivity to radiation, and has shown promise in similar animal studies of glioblastoma" said M. Karen Newell Rogers, Ph.D. Chief Scientific Consultant for Global Cancer Technology and a Professor and Immunologist at Texas A&M University.

"We were highly impressed with preclinical in vitro studies previously completed by others in glioblastoma and look forward to testing the compound in similar studies in an in vivo animal model of breast cancer that we will be performing", said Dr. Lyons".

"Global Cancer Technology is fortunate to be supported by the great research that Dr. Lyons conducts in breast cancer at the University of Colorado, and we look forward to her *in vivo* results as we all work together to find a cure for this dreaded form of breast cancer" said John Clark, the CEO of Global Cancer Technology. Mr. Clark further added, "We have achieved very compelling data for the drug's use in glioblastoma, and we hope to be in as phase I clinical trial for triple negative breast cancer and glioblastoma at some point in 2024".

---

*Global Cancer Technology is a non-revenue biopharma company that is currently raising investment capital to enter a Phase 1 clinical trial.*

*Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized*